Clinical Trial Update: 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating 17-N-allylamino-17-demethoxygeldanamycin in adults with solid tumors that are not resectable, including lymphoma, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumor

Drugs mentioned

• 17-N-Allylamino-17-Demethoxygeldanamycin (tanespimycin)

Snippet

Sponsor: Mayo Clinic | Conditions: Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Status: COMPLETED